Clinical Trial: Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07777822) titled 'Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC' on Aug. 17.

Brief Summary: The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Study Start Date: Aug. 14

Study Type: INTERVENTIONAL

Condition: NSCLC Non-small Cell Lung Cancer Non-Small Cell Lung Cancer NSCLC Non-Squamous Non Small Cell Lung Cancer...